医用纳米与基因药物口服化的探索

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (3): 241-249.

• 专论 • 下一篇

医用纳米与基因药物口服化的探索

许瑞安

国立华侨大学分子药物学研究所(院), 泉州362021, 福建

收稿日期:2007-02-20 修回日期:2007-03-26 出版日期:2007-03-26 发布日期:2020-11-06
作者简介:许瑞安教授, 华侨大学分子药物学研究所(院) 所长、教授、博士生导师, Otago 大学博士, 国际癌细胞与基因疗法学会常务理事, 新西兰食品科学技术研究院专业委员, 爱尔兰国家自然基金评审专家, 《中国临床药理学与治疗学》编委、顾问, “ 行政院” 台北荣民总院荣誉教授, 中国海洋大学海洋药物客座教授, 北京协和医学院、山东大学兼职教授, 国家863“十五”肺癌基因疗法课题组组长、首席科学家, 肝癌基因疗法课题组副组长, 为口服基因疗法主要奠基人之一。其分子药学与分子药理学部分研究成果发表于Nature Medicine 、Science 、PNAS 等国际一流学术刊物。近五年内发表SCI 国际论文21 篇(影响因子>120分), 并申报美等国专利7 项。主编《分子基因药物学》(北京大学出版社与北京大学医学出版社联合出版),《细胞与分子生物技术》, 合编《Trends in Gene Therapy Research》(NOVA Science Publisher, New York, USA, 2005) 。E-mail:ruianxu@hqu.edu.cn

Development of clinical nano-particles and oral gene medicine

XU Rui-an

Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, Fujian, China

Received:2007-02-20 Revised:2007-03-26 Online:2007-03-26 Published:2020-11-06

摘要/Abstract

摘要： 口服给药乃是疾病防治的主要手段之一^[1],由于方便、有效、舒适、安全受到患者与医生的普遍欢迎。但是大分子药物在肠道的摄取和吸收仍然缺乏详尽的有效研究。最近十多年来, 利用纳米技术开展大分子药物在肠道的摄取和吸收取得了可喜的进展。本文系统地阐述纳米颗粒、蛋白转导、纳米微粒在肠道的摄取位点、摄取细胞种类与吸收的关系。本文对口服给药基因治疗这一新颖的给药途径的探索予以重点介绍, 并讨论了目前口服基因药物传递及基因表达的主要障碍和未来发展趋势。

关键词: 医用纳米, 基因, 药物, 口服, 治疗

Abstract: Oral medicine is one of the main methods for disease prevention and treatment.It is very popular in healthcare due to its convenience, efficiency, comfort and safety.However, there is still a lack of qualitative and quantitative information how about macro-molecules, and nano-particles in particular, are taken up and absorbed in the gastrointestinal tract.This paper systematically describes relationships between features of nano-particles, protein transduction, and uptake cell types at gastrointestinal sites and the uptake and absorbance of nano-particles.Development of the route for orally-delivered gene medicine, and particularly the uptake, distribution, pharmakinetics, feasibility and system evaluation of orally viral vectors is explored.Trends in and obstacles to the delivery, expression, production and release of oral gene medicine are also discussed.

Key words: clinical, nano-particles, oral, gene, medicine, therapy

中图分类号:

R966

许瑞安. 医用纳米与基因药物口服化的探索[J]. 中国临床药理学与治疗学, 2007, 12(3): 241-249.

XU Rui-an. Development of clinical nano-particles and oral gene medicine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 241-249.

参考文献

1 许瑞安, 肖卫东, 主编.分子基因药物学[M].北京大学&北京大学医学出版社联合出版, 2007:1-28.
2 Page DT, Cudmore S.Innovations in oral gene delivery:challenges and potentials[J].Drug Discov Today, 2001;6:92-101.
3 Delie F.Evaluation of nano-and microparticle uptake by the gastrointestinal tract[J].Adv Drug Deliv Rev, 1998;34:221-233.
4 Pappo J, Ermak TH.Uptake and translocation of fluorescent latex particles by rabbit Peyer' s patch follicle epithelium:a quantitative model for M cell uptake[J].Clin Exp Immunol, 1989; 76:144-148.
5 Florence AT, Hillery AM, Hussain N, et al.Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence[J].J Drug Target, 1995;3: 65-70.
6 Frey A, Giannasca KT, Weltzin R, et al.Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells:implications for microbial attachment and oral vaccine targeting[J].J Exp Med, 1996;184: 1045-1059.
7 Desai MP, Labhasetwar V, Amidon GL, et al.Gastrointestinal uptake of biodegradable microparticles:effect of particle size [J].Pharm Res, 1996;13:1838-1845.
8 Bonduelle S, Carrier M, Pimienta C, et al.Tissue concentration of nanoencaps ulated radiolabeled cyclosporin following peroral delivery in mice or ophthalmic application in rabbits[J]. Eur J Phar Biopharm, 1996;42:313-319.
9 Nefzger M, Kreuter J, Voges R, et al.Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats[J].J Pharm Sci, 1984;73:1309-1311.
10 Wells Cl, MaddausMA, Erlandsen SL, et al.Evidence for the phagocytic transport of intestinal particles in dogs and rats[J]. Infect Immun, 1988;56:278-282.
11 Smith MW, James PS, Tivey DR.M cell numbers increase after transfer of SPF mice to a normal animal house environment [J].Am J Pathol, 1987;128:385-389.
12 JepsonMA, ClarkMA, Foster N, et al.Targeting to intestinal M cells[J].J Anat, 1996;189:507-516.
13 Brayden DJ, Baird AW.Apical membrane receptors on intestinal M cells:potential targets for vaccine delivery[J].Adv Drug Deliv Rev, 2004;56:721-726.
14 Pinto-Alphandary H, Aboubakar M, Jaillard D, et al.Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats[J].Pharm Res, 2003; 20:1071-1084.
15 Rescigno M, Urbano M, Valzasina B, et al.Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria[J].Nat immunol, 2001;2:361-367.
16 Green M, Loewenstein PM.Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein[J].Cell, 1988;55:1179-1188.
17 Frank AD, Pabo CO.Cellular uptake of the tat protein from human immunodeficiency virus[J].Cell, 1988;55:1189-1193.
18 熊符, 张成, 于美娟.蛋白转导在基因治疗中的应用[J].国际生物学工程杂志, 2006;29:250-254.
19 Efrat S, Surana M, Fleischer N.Glucose induces insulin gene transcription in a murine pancreatic beta-cell line[J].J Biol Chem, 1991;266:11141-11143.
20 Del G, Moore V, Payne RM.Transactivator of transcription fusion protein transduction causes membrane inversion[J].J Biol Chem, 2004;179:32541-32543.
21 Eguchi A, Akurta T, Okuyama H.et al.Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells[J].J Biol Chem, 2001;276:26204-26210.
22 Lambkin I, Pinilla C.Targeting approaches to oral drug delivery[J].Expert Opin Biol Ther, 2002;2:67-73.
23 Thanos CG, Liu Z, Reineke J, et al.Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride[J].Pharm Res, 2003;20:1093-1100.
24 Vajdy M, O' Hagan DT.Microparticles for intranasal immunization[J].Adv Drug Delib Rev, 2001;51:127-141.
25 Eldridge JH, Meulbroek JA, Staas JK, et al.Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response[J].Adv ExpMed Biol, 1989;251:191-202.
26 Giannasca PJ, Giannasca KT, Leichtner AM, et al.Human intestinalM cells display the sialyl Lewis A antigen[J].Infect Immu, 1999;67:946-953.
27 Wu Y, Wang X, Csencsits KL, et al.M cell-targeted DNA vaccination[J].Proc Natl Acad Sci US A, 2001;98:9318-9323.
28 Tyler KL, Clarke P, DeBiasi RL, et al.Reoviruses and the host cell[J].Trends Microbiol, 2001;9:560-564.
29 Heppner FL, Christ AD, Klein MA, et al.Transepithelial prion transport by M cells[J].Nat Med, 2001;7:976-977.
30 Heggebo R, Gonzalez L, Press CM, et al.Disease-associated PrP in the enteric nervous system of scrapie-affected Suffolk sheep[J].J Gen Virol, 2003;84:1327-1338.
31 Terry LA, Marsh S, Ryder SJ, et al.Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy[J].Vet Rec, 2003;152: 387-392.
32 Huang FP, Farquhar CF, Mabbott NA, et al.Migrating intestinal dendritic cells transport PrP(Sc) from the gut[J].J Gen Virol, 2002;83:267-271.
33 Ghosh S.Intestinal entry of prions[J].Z Gastroenterol, 2002; 40:37-39.
34 Shmakov AN, Bode J, Kilshaw PJ, et al.Diverse patterns of expression of the 67-kD laminin receptor in human small intestinal mucosa:potential binding sites for prion proteins[J] ? J Pathol, 2000;191:318-322.
35 El-Bahi S, Caliot E, BensM, et al.Lymphoepithelial interactions trigger specific regulation of gene expression in the M cellcontaining follicle-associated epithelium of Peyer' s patches[J]. J Immunol, 2002;168:3713-3720.
36 Kerneis S, Bogdanova A, Kraehenbuhl JP, et al.Conversion by Peyer' s patch lymphocytes of human enterocytes into M cells that transport bacteria[J].Science, 1997;277:949-952.
37 Fotopoulos G, Harari A, Micheetti P, et al.Transepithelial transport of HIV-1 by M cells is receptor-mediated[J].Proc Natl Acad Sci USA, 2002;99:9410-9414.
38 Ouzilou L, Caliot E, Pelletier I, et al.Poliovirus transcytosis through M-like cells[J].J Gen Virol, 2002;83:2177-2182.
39 Iwasaki A, Welker R, Mueller S, et al.Immunofluorescence analysis of poliovirus receptor expression in Peyer' s patches of humans, primates, and CD155 transgenic mice:implications for poliovirus infection[J].J Infect Dis, 2002;186:585-592.
40 Lelouard H, Reggio H, Roy C, et al.Glycocalyx on rabbit intestinalM cells displays carbohydrate epitopes from Muc2[J]. Infect Immun, 2001;69:1061-1071.
41 Xu RA, Ma H, Li H, et al.Trends in Gene Ther Res[M]. New York:NOVA Science Publisher, 2006.
42 Takamura S, Niikura M, Li TC, et al.DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and sy stemic immune responses by oral administration[J].Gene Ther, 2004;11:628-635.
43 Xu RA, Janson CG, Mastakov M, et al.Quantitative compareson of expression with adeno-associated virus (AAV-2) brainspecific gene cassettes[J].Gene Ther, 2001;8:1323-1332.
44 During MJ, Xu RA, Young D, et al.Peroral gene therapy of lactose intolerance using an adeno-associated virusvector[J]. NatMed, 1998;4:1131-1136.
45 Xu RA, Herrison P, Chen M, et al.Cytoglobin protects against damage-induced liver fibrosis[J].Mol Ther, 2006;13: 1093-1100.
46 During MJ, Symes CW, Lawlor PA, et al.An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy[J].Science, 2000;287:1453-1560.
47 Xu RA.Oral gene delivery for cancer therapy[J].Cancer Gene Ther, 2004;11:843.
48 Shenk T.Adenoviridae:the viruses and their application[M]. Fundamental Virology.Third edition.Philadelphia:Lippincott-Raven Publishers, 1996:888-994
49 Ogawara K, Rots MG, Kok RJ, et al.A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo[J].Human Gene Therapy, 2004;15:433-443.
50 MinekusM, Marteau P, Havenaar R, et al.A multi-compartmental dynamic computer-controlled model simulating the stomach and small intestine[J].ATLA, 1995;23:197-209.
51 Steidler L, HansW, Schotte L, et al.Treatment of murine colitis by Lactococcus lactis secreting interleukin-10[J].Science, 2000;289:1352-1355.

[1]	汪飞, 杭永付, 王未. 重症患者肾功能亢进对替考拉宁血药浓度影响分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1043-1048.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[4]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[5]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[6]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[7]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[8]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[9]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[10]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[11]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[12]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[13]	吴雄志, 王宣, 徐四七, 居霞, 王胜斌, 陈永权. 咪达唑仑口服溶液比右美托咪定喷鼻更有效缓解儿童术前焦虑[J]. 中国临床药理学与治疗学, 2023, 28(6): 666-670.
[14]	赵璐, 李付勇, 温滨红, 李道伟. 他汀类药物治疗伴高脂血症偏头痛患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2023, 28(6): 671-675.
[15]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.

医用纳米与基因药物口服化的探索

Development of clinical nano-particles and oral gene medicine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价